|Articles|January 15, 2007

Sirion launches trial

Sirion Therapeutics has begun enrolment for a Phase II trial of the compound fenretinide, as a treatment for geographic atrophy in patients with age-related macular degeneration.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Latest CME